PL411390A1 - Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej - Google Patents

Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej

Info

Publication number
PL411390A1
PL411390A1 PL411390A PL41139015A PL411390A1 PL 411390 A1 PL411390 A1 PL 411390A1 PL 411390 A PL411390 A PL 411390A PL 41139015 A PL41139015 A PL 41139015A PL 411390 A1 PL411390 A1 PL 411390A1
Authority
PL
Poland
Prior art keywords
diabetes
type
level
wnt4
wnt3a
Prior art date
Application number
PL411390A
Other languages
English (en)
Inventor
Agnieszka Dobrzyń
Kamil Koziński
Original Assignee
Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk filed Critical Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk
Priority to PL411390A priority Critical patent/PL411390A1/pl
Priority to US15/553,575 priority patent/US10222384B2/en
Priority to PL16714534T priority patent/PL3262420T3/pl
Priority to EP16714534.1A priority patent/EP3262420B1/en
Priority to PCT/IB2016/051087 priority patent/WO2016135702A1/en
Priority to ES16714534T priority patent/ES2731294T3/es
Publication of PL411390A1 publication Critical patent/PL411390A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sposób wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu drugiego, charakteryzuje się tym, że obejmuje ocenę poziomu białka wybranego spośród Wnt4 i Wnt3a w próbce biologicznej pochodzącej od pacjenta, zwłaszcza w osoczu, przy czym odbiegający od normy poziom tego białka wskazuje na występowanie stanu przedcukrzycowego lub cukrzycy typu drugiego, przy czym korzystnie uznaje się, że: o stanie przedcukrzycowym świadczy obniżony poziom Wnt4 lub podwyższony poziom Wnt3a, lub występowanie tych zaburzeń jednocześnie, o cukrzycy, zwłaszcza typu drugiego, świadczy podwyższony poziom Wnt4 i obniżony poziom Wnt3a. Przedmiotem zgłoszenia jest również zastosowanie poziomu białka wybranego spośród Wnt4 i Wnt3a, zwłaszcza w osoczu, do identyfikowania stanu przedcukrzycowego lub cukrzycy.
PL411390A 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej PL411390A1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL411390A PL411390A1 (pl) 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
US15/553,575 US10222384B2 (en) 2015-02-26 2016-02-26 Method for the early diagnosis of a pre-diabetic state and type 2 diabetes
PL16714534T PL3262420T3 (pl) 2015-02-26 2016-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2
EP16714534.1A EP3262420B1 (en) 2015-02-26 2016-02-26 A method for the early diagnosis of a pre-diabetic state and type 2 diabetes
PCT/IB2016/051087 WO2016135702A1 (en) 2015-02-26 2016-02-26 A method for the early diagnosis of a pre-diabetic state and type 2
ES16714534T ES2731294T3 (es) 2015-02-26 2016-02-26 Método para el diagnóstico precoz de un estado prediabético y de diabetes tipo 2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411390A PL411390A1 (pl) 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej

Publications (1)

Publication Number Publication Date
PL411390A1 true PL411390A1 (pl) 2016-08-29

Family

ID=55661489

Family Applications (2)

Application Number Title Priority Date Filing Date
PL411390A PL411390A1 (pl) 2015-02-26 2015-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
PL16714534T PL3262420T3 (pl) 2015-02-26 2016-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16714534T PL3262420T3 (pl) 2015-02-26 2016-02-26 Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2

Country Status (5)

Country Link
US (1) US10222384B2 (pl)
EP (1) EP3262420B1 (pl)
ES (1) ES2731294T3 (pl)
PL (2) PL411390A1 (pl)
WO (1) WO2016135702A1 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
JP2010519913A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｗｎｔ遺伝子の発現を抑制するための核酸化合物およびその使用
JP5246870B2 (ja) * 2009-03-25 2013-07-24 独立行政法人産業技術総合研究所 インシュリン産生増強剤
BR112013020274A2 (pt) 2011-02-10 2016-11-22 Harvard College substitutos de proteínas pós-traducionalmente modificadas e usos dos mesmos

Also Published As

Publication number Publication date
EP3262420A1 (en) 2018-01-03
US10222384B2 (en) 2019-03-05
US20180017574A1 (en) 2018-01-18
WO2016135702A1 (en) 2016-09-01
PL3262420T3 (pl) 2019-11-29
EP3262420B1 (en) 2019-03-20
ES2731294T3 (es) 2019-11-14

Similar Documents

Publication Publication Date Title
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
HK1222780A1 (zh) 具有微流体系统的眼科镜片
MX2025006655A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
IN2014DE01077A (pl)
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
MX380642B (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
WO2017025617A8 (en) Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
BR112016017926A2 (pt) ensaio para detectar periostina humana
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
MX376501B (es) Adn huésped como biomarcador de la enfermedad de crohn.
MX384636B (es) Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano.
AU2018357933B2 (en) Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
PL411390A1 (pl) Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации